2
Turbine Expands Scientific Advisory Board to Put Virtual Disease Models in Every Scientist’s Hands
10 July 2025
LONDON and BUDAPEST, HUNGARY – July 10, 2025 – Turbine, the company virtualizing experiments with AI to accelerate discovery and clinical decisions, today announced the addition of Andrew Pape, PhD and Gregory Vladimer, PhD to its Scientific Advisory Board. Together, they bring decades of strategic and translational biology expertise to accelerate Turbine’s mission: enabling drug discovery teams to run smarter preclinical experiments that increase the likelihood of clinical success and stay several steps ahead in the process.
Most experimental models fail to capture the biology that matters, leading to widespread Phase II failures. Turbine’s simulation platform, built over the past decade, empowers researchers to generate and test hypotheses on highly accurate virtual disease models – the next best thing to real patients. By integrating multimodal data in real time and using a lab-in-the-loop workflow for both validation and simulation-guided data generation, Turbine uncovers critical mechanisms traditional model systems often miss. As the first adopter in the region of Revvity’s automated system, Turbine is generating high-quality, AI-ready training data that scientists can use to quickly iterate on virtual cells tailored to multiple questions. The result is a scalable, agile platform that transforms what happens before the wet lab – putting smarter, more predictive experiments directly into the hands of pharma scientists.
New expertise to scale a lab-in-the-loop future
Scaling this vision takes more than technology, it requires deep expertise in oncology, translational biology, and pharma strategy. Two exceptional additions to Turbine’s Scientific Advisory Board bring tangible industry experience and knowledge:
- Andrew Pape, PhD; formerly Vice President Strategy, Oncology R&D at AstraZeneca, Andrew played a central role in shaping one of the most successful oncology portfolios in the market. His strategic leadership was instrumental in defining the future direction of Oncology R&D where he worked closely with Early Oncology, Late Development and the Oncology Business Unit. At Turbine, he will sharpen strategic alignment, inform the product roadmap and guide platform adoption with a deep understanding of partner needs.
- Gregory Vladimer, PhD; brings hands-on experience with patient-derived samples, fit-for-purpose data generation, and lab-integrated translational systems, capabilities that are directly aligned with Turbine’s mission. He served as VP of Translational Research at Exscientia and was previously CSO of Allcyte, both of which leveraged primary cancer models and custom-designed data to drive oncology predictions. At Exscientia, he contributed to one of the tech-bio field’s most instrumental stories through a blend of translational insight and company-building expertise. Gregory now helps Turbine scale its proprietary data generation capabilities to ground simulations in rich datasets that reflect the biological rules translatable to patients.
Today’s SAB expansion marks the next phase: putting those virtual disease models in every scientist’s hands, supporting a single program, an entire therapeutic area, or an organization’s full pipeline.
About Turbine
Turbine is virtualizing experiments with AI to accelerate discovery and clinical decisions. We’ve spent the last decade building virtual disease models that we believe are second only to the patient in predicting drug response. By simulating how cells and tissues behave under treatment, Turbine helps pharma identify the right therapeutic ideas smarter and faster, cutting years of dead-end research and reducing Phase II failure caused by poor efficacy. Scientists can now run billions of virtual experiments to uncover risk, design smarter trials, and scale decisions across entire pipelines. Validated through partnerships with Bayer, AstraZeneca, Merck, and others, Turbine’s platform has supported nearly 30 research programs and grown revenue from €400K to €2.9M in the past year. Backed by Accel, MSD Global Health Innovation Fund, and a major U.S. bio-tech family office, we’re putting predictive simulations in the hands of every scientist.
back